Charity's Patient Assistance Program Passes OIG Muster in Advisory Opinion 15-17

by Baker Ober Health Law

On December 28, 2015, the Department of Health and Human Services, Office of Inspector General (OIG) issued OIG Advisory Opinion 15-17 [PDF], approving a charity’s proposal to unveil a new patient assistance program dedicated to supporting patients with a specified disease state (Specified Disease). In light of the numerous safeguards proposed by the charity, the OIG concluded the arrangement would likely pose a low risk under both the federal anti-kickback statute and the civil monetary penalty provision prohibiting inducements to beneficiaries (Beneficiary Inducement CMP).

Overview of the Proposed Patient Assistance Program

Under the proposed patient assistance program, the charity will assist financially needy patients, including Medicare and Medicaid beneficiaries, with their copayment and coinsurance obligations, health insurance premiums, and deductibles for outpatient prescription drugs used to treat the Specified Disease. The Specified Disease is, as represented by the charity, a “broadly defined” disease state based on “widely recognized clinical standards,” without reference to specific symptoms, severity of symptoms, method of administration of drugs, or type of drug treatment.

The charity intends to disseminate information regarding the proposed patient assistance program via patients’ treating physicians, written material to be placed in physicians’ offices, and direct online outreach by the charity itself. Participation in the proposed program will be limited in accordance with the following parameters:

  • Patients diagnosed with Stage 3 or Stage 4 of the Specified Disease: Eligibility in the program will be limited to patients diagnosed with Stage 3 or Stage 4 of the Specified Disease. That said, financial assistance will not be limited to only those drugs expressly approved for Stage 3 or Stage 4 of the Specified Disease.

  • Patients must already have a treating provider: To participate in the proposed program, patients must have already selected a health care provider, practitioner, or supplier, with a treatment regimen in place. While enrolled in the proposed program, patients will remain free to change their providers, practitioners, suppliers, drugs, and insurance plans.

  • Financial need, in accordance with federal poverty guidelines: In line with the charity’s stated intent to apply a “reasonable, verifiable, and uniform measure of financial need,” patient eligibility will be based on financial need, in accordance with the federal poverty level guidelines. The charity will employ a screening process to verify applicants’ representations, relying on either a third-party vendor and/or directly collecting documentation of financial resources from the patient.

The charity certified that under no circumstances would patient eligibility be determined based in whole or in part on (a) the interest of a donor; (b) the patient’s choice of provider, practitioner, supplier, drug, or insurance plan; or (c) the identity of the referring person or entity. In further support of patient choice, the charity certified that it “would not refer patients to, recommend, or arrange for the use of any particular provider, practitioner, supplier, drug, or insurance plan….”

Upon meeting the eligibility criteria, patients would be approved to participate in the charity’s patient assistance program on a first-come, first-served basis, for a term of one year. Patients could participate for a second year upon the charity re-verifying the patient’s financial need, and the patient submitting documentation from his or her physician indicating treatment for the Specified Disease remains ongoing.

Charitable contributions to the proposed patient assistance program would come largely from pharmaceutical manufacturers. However, the charity certified that no donor to the charity or affiliate of any donor directly or indirectly influenced the identification of the proposed Specified Disease fund. In support of this certification, the charity stated that (a) the charity prohibits all donors from earmarking their donations to support a particular drug or type of cost-sharing obligation; (b) donors are able to change or discontinue their contributions to the charity at any time; and (c) multiple drugs, marketed by different pharmaceutical manufactures, are available to treat the Specified Disease, each of which the charity would provide financial assistance for. In addition, the charity is governed by an independent board of directors, in which no donor or affiliate of a donor (including former directors, officers, or employees of a donor who maintain an ongoing relationship with a donor), exerts direct or indirect influence.

The charity would provide donors to the Specified Disease fund with data outlining the aggregate number of applicants, patients served, and the amount of funds used. The data provided would not allow for a donor to assess the impact of its donation on the use of its drugs. Patients would not receive any information about donors and donors would not receive any information about other donors.

Anti-kickback Statute

The OIG concluded the charity’s proposed patient assistance program would pose a “minimal risk” under the anti-kickback statute – that is, given the program safeguards proposed by the charity, it was unlikely that any donors’ contribution to the charity would be construed as payments to arrange for referrals to the donor. In reaching its conclusion, the OIG highlighted the following factors:

  • The charity’s independence from donors: No donor (or affiliate of any donor) exerts control over the charity, as evidenced by the fact that (a) the charity retains independence in how it may use a donor’s contribution; (b) no donor exerted influence in selecting the Specified Disease fund; and (c) the charity’s board remains independent of any donor’s or donor affiliate’s influence.

  • Participating patients will already have a treatment regimen in place: In order to participate in the charity’s proposed program, patients must have selected a health care provider, practitioner, or supplier. Accordingly, the patient will already have a treatment regimen in place. In addition, the charity itself may not refer patients to, recommend, or arrange for, the use of a particular practitioner, provider, supplier, drug, or insurance plan. Also, participating patients remain free to change their health care provider, supplier, drug, or insurance plan. As such, participation in the charity’s proposed program will not influence a patient’s selection of a particular practitioner, provider, supplier, drug, or insurance plan.

  • Donors receive limited data: Under the proposed program, the data provided by the charity to donors will be limited to the aggregate number of applicants for financial assistance, the number of patients served, and the total amount of funds used for financial assistance. Donors will not receive data that would allow them to specifically correlate their donations with the use of their respective drug(s). Likewise, patients will not receive any information regarding donors.

  • Donors’ lack of involvement in selecting the disease state: The charity certified that no donor, or affiliate of any donor, directly or indirectly, influenced the identification of the Specified Disease and corresponding disease fund. In support of this certification, the OIG looked to the fact that the disease fund is broadly defined and is based on “widely recognized clinical standards” for a “broad spectrum of available drugs.” While the disease fund would be limited to patients in stage 3 or stage 4 of the Specified Disease, it would not otherwise be limited by specific symptoms, etc., and financial assistance would be available for all drugs, including generic or bioequivalent drugs used to treat any stage of the Specified Disease.

The above factors, the OIG concluded, would provide “sufficient insulation,” such that it would be unlikely the charity’s proposed arrangement would serve as a “disguised conduit” in which a pharmaceutical manufacturer would seek to induce patients to use its drugs.

Beneficiary Inducement CMP

Similar to the anti-kickback statute analysis, the OIG concluded that the charity’s proposed arrangement presents a low risk under the Beneficiary Inducement CMP.

In doing so, the OIG first emphasized that patient eligibility would be based solely on financial need, to be verified by the charity using a screening process. Eligibility would be in no way linked to (a) the identity of a patient’s health care provider, supplier, drug, or insurance plan; (b) the identity of any referring party; or (c) the identity of any donor to the Specified Disease fund. Rather, participating patients must have already selected a provider, practitioner, or supplier, prior to enrolling in the proposed arrangement. Consequently, the charity’s proposed arrangement would be unlikely to influence a participating patient’s selection of a provider, practitioner, or supplier for items or services paid by Medicare or a state health care program.

Second, the OIG highlighted the fact that the charity itself would remain wholly removed from any decisions related to participating patient’s medical treatment, and would not refer patients to, recommend, or arrange for the use of any particular practitioner, provider, supplier, drug, or insurance plan. Participation in the program would remain on a first-come, first-served basis, to the extent a patient met the charity’s financial need criteria and funding remained available. This too, the OIG concluded, would safeguard against the charity’s proposed program from influencing a participating patient’s selection of a provider, practitioner, or supplier for items or services paid by Medicare or s state health care program.

Ober|Kaler's Comments

Advisory Opinion 15-17 is consistent with the OIG’s long-standing approval of nonprofit, tax-exempt, charitable organizations providing assistance with out-of-pocket expenses for prescription drugs to financially needy patients that meet certain criterias. While the OIG continues to emphasize the importance of the patient assistance program being focused on a broadly defined disease state, in Advisory Opinion 15-17 the OIG approved a program that was limited to Stage 3 and Stage 4 of the specified disease state.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Ober Health Law | Attorney Advertising

Written by:

Baker Ober Health Law

Baker Ober Health Law on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.